Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 6:51 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1345–1368 of 3,875 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: fast Clear all

Conditions: Health Behavior
Interventions: peer counseling, Feedback report; Behavioral
Lead sponsor: Boston Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Multiple Myeloma
Interventions: Tasquinimod, IRd chemotherapy; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Schizophrenia
Interventions: Asenapine, Placebo Asenapine, Olanzapine, Placebo Olanzapine; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 18 Years and older
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Herpes Simplex Virus 2
Interventions: Not listed
Lead sponsor: Focus Diagnostics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 400 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: Burbank, California

Conditions: Non Hodgkin Lymphoma
Interventions: UF-KURE19 CAR-T cells, Fludarabine, Cyclophosphamide; Biological · Drug
Lead sponsor: David Wald; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 3
States / cities: Iowa City, Iowa • Cleveland, Ohio

Conditions: Distal Radius Fracture, Osteoporosis, Hip Fractures
Interventions: Reference Point Indentation; Device
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 50 Years to 100 Years
Enrollment: 190 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2030
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Healthy
Interventions: Gabapentin 400 mg capsules, NEURONTIN® 400 mg capsules; Drug
Lead sponsor: Actavis Inc.; Industry
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1998
U.S. locations: 1
States / cities: Saint Charles, Missouri

Conditions: Breast Cancer
Interventions: Physical Evaluation, Dual-energy X-ray absorptiometry scans, Trabecular Bone Score; Other · Diagnostic Test
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Healthy
Interventions: BI 691751 fasted, BI 691751 after high fat breakfast; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 50 Years · Male only
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Covid19, Hydroxychloroquine, Coronavirus Infection, Transmission, Prophylaxis
Interventions: Hydroxychloroquine; Drug
Lead sponsor: Bryn Mawr Hospital; Other
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 3
States / cities: Bryn Mawr, Pennsylvania • Paoli, Pennsylvania • Wynnewood, Pennsylvania

Conditions: Gastroesophageal Reflux
Interventions: Cognitive Behavioral Therapy, Sham-SOC Lifestyle Coaching; Other
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 2
States / cities: Chicago, Illinois • St Louis, Missouri

Conditions: Cocaine-Related Disorders
Interventions: Baclofen; Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1997
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Bipolar I Disorder
Interventions: Not listed
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 423 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 9
States / cities: Costa Mesa, California • Cromwell, Connecticut • Doral, Florida + 5 more

Conditions: Healthy
Interventions: Sumatriptan Succinate Tablets 100 mg, Imitrex® Tablets 100 mg; Drug
Lead sponsor: Mylan Pharmaceuticals Inc; Industry
Eligibility: 18 Years and older
Enrollment: 55 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004
U.S. locations: 1
States / cities: Morgantown, West Virginia

Conditions: Healthy
Interventions: Single dose of PF-07104091 as Tablet Formulation A (Treatment A), Single dose of PF-07104091 as Tablet Formulation B (Treatment B), Single dose of PF-07104091 as Tablet Formulation C (Treatment C), Single dose of PF-07104091 as Tablet Formulation D (Treatment D), Single dose of PF-07104091 as Tablet Formulation C (Treatment E); Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 60 Years · Male only
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Glycemia
Interventions: Berberine, Dihydroberberine 200, Dihydroberberine 100, Placebo; Dietary Supplement
Lead sponsor: Lindenwood University; Other
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 5 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Saint Charles, Missouri

Conditions: Infection, Skin and Subcutaneous Tissue Bacterial Infections, Healthcare-associated Infection, Infection Due to Resistant Bacteria
Interventions: Not listed
Lead sponsor: Connie Price; Other
Eligibility: 18 Years and older
Enrollment: 2,298 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 3
States / cities: Denver, Colorado • Washington D.C., District of Columbia

Conditions: Vascular Access Complication
Interventions: RIVS vascular access, Conventional vascular access; Device
Lead sponsor: C. R. Bard; Industry
Eligibility: 5 Years to 90 Years
Enrollment: 175 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2013
U.S. locations: 3
States / cities: Fremont, California • Jacksonville, Florida • Cleveland, Ohio

Conditions: Heart Failure
Interventions: Triage® B-Type Natriuretic Peptide (BNP) Test; Device
Lead sponsor: Abbott RDx Cardiometabolic; Other
Eligibility: 18 Years and older
Enrollment: 720 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2006
U.S. locations: 29
States / cities: Scottsdale, Arizona • San Diego, California • San Francisco, California + 25 more

Conditions: Lymphoma
Interventions: milatuzumab, veltuzumab, Correlative/Special Studies, Quantitative T-, B-, and NK cell subsets, Pharmacokinetics, Human Anti-Human Antibodies, veltuzumab and milatuzumab; Biological · Procedure
Lead sponsor: Beth Christian; Other
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Substance Use, HIV Infections
Interventions: Communication skills training video, Drug use module; Behavioral
Lead sponsor: Hunter College of City University of New York; Other
Eligibility: 17 Years to 29 Years · Male only
Enrollment: 484 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2026
U.S. locations: 2
States / cities: Ann Arbor, Michigan • New York, New York

Conditions: Cystic Fibrosis
Interventions: micro Sweat Test Patch (mSTP), Sweat Testing using SOC; Device · Diagnostic Test
Lead sponsor: Emory University; Other
Eligibility: 2 Weeks to 90 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 2
States / cities: Atlanta, Georgia

Conditions: Irritable Bowel Syndrome
Interventions: Elemental Diet; Dietary Supplement
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 18 Years to 85 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Lymphoma, Lymphoma, B-Cell
Interventions: Rituximab, Etoposide, Prednisone, Vincristine, Cyclophosphamide, Doxorubicin, CAPP-seq; Drug · Device
Lead sponsor: Jennifer Amengual; Other
Eligibility: 15 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 2
States / cities: Stanford, California • New York, New York

Search by objective public record fields.

Nutrition and Physical Activity Counseling for Nontraditional College Students

Tasquinimod for the Treatment of Relapsed or Refractory Myeloma

Long-Term Safety Extension Trial of Asenapine in Schizophrenia Participants Who Completed Protocol P05688 (P05689)

HerpeSelect® Express Rapid Test Study Protocol: Sexually Active Adult Population

Evaluate the Safety of UF-KURE19 Cells in Non-Hodgkin Lymphomas

Utility of Cortical Bone Tissue Properties in the Assessment of Fracture Risk

A Relative Bioavailability Study of Gabapentin 400 mg Capsules Under Fasting Conditions

Observational Study of Bone Complications in People With Post-menopausal Breast Cancer Who Have Stopped Treatment With Denosumab and Aromatase Inhibitors

Relative Bioavailability of BI 691751 Administered With and Without Food to Healthy Male Subjects

Rapid Development and Implementation of a Remote ECG-monitored Prospective Randomized Clinical Trial During a Pandemic: Hydroxychloroquine Prophylaxis in COVID-19 Household Contacts

Targeting Hypervigilance and Autonomic Arousal: the Psycho-physiologic Model of Gastroesophageal Reflux Disease (GERD)

Rapid Evaluation of Baclofen for Treatment of Cocaine Abuse/Dependence - 6

Study to Assess Accuracy of Rapid Mood Screener in Adult Participants With Unipolar Major Depressive Disorder or Bipolar 1 Disorder in Real World Setting

Fasting Study of Sumatriptan Succinate Tablets 100 mg to Imitrex® Tablets 100 mg

A Study to Investigate the Effect of Tablet Formulation and Food on PF-07104091 in Healthy Participants

Bioavailability of Berberine and Dihydroberberine and Their Impact on Glycemia

Study of Accuracy of New Diagnostic Technology to Determine Guide Rapid Antibiotic Treatment for Serious Infections

Effectiveness of the Rapid Intravascular Start (RIVS) System Versus Conventional Catheter

Rapid Assessment of Bedside BNP In Treatment of Heart Failure (RABBIT)

Veltuzumab and Milatuzumab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Expanding the Potential of Couples HIV Testing: Adjunct Modules to Reduce Drug Use Among Vulnerable Male Couples

Novel Point-of-care Sweat Chloride Testing Device for Monitoring CFTR Function

Elemental Diet and Gut Microbiome

Defining ctDNA Metrics in Posttransplant Lymphoproliferative Disorder (PTLD)